Analysis shows that the JADA device cuts healthcare costs related to postpartum haemorrhage, indicating improved economic efficiency.
Introduction: Postpartum Haemorrhage (PPH) represents one of the leading causes of maternal mortality globally. In addition to standard guidelines treatments of PPH, the JADA® device has proven to be clinically and economically effective. The objective of this study was to develop a budget impact model (BIM) to assess the economic impact of the introduction of the JADA® device in the Italian context.Methods: The analysis was developed through a 3-year budget impact model through the perspective of theNational Health System. The model considered three different treatment strategies: 1) administration of uterotonics/ tranexamic acid and application of the uterine balloon tamponade; 2) administration of uterotonics/tranexamic acid only; 3) administration of uterotonics/tranexamic acid and use of the JADA® device. For eachstrategy, in case of failure to stop bleeding, the model included the transition of patients to surgical procedures.Cost estimates were obtained considering a PPH rate of 10%.Results: The introduction of the JADA® device for the management of PPH would generate a significant reductionin healthcare expenditure, with a cumulative saving of 32.96 million € over 3 years and total savings of 295.64 €per eligible birth.Conclusions: The analysis showed that the introduction of the JADA® device for the management of PPH in Italycould lead to a reduction in the healthcare expenditure.
No takes yet. Share an insight, caveat, or question.
Marcellusi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: